These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8622070)

  • 1. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
    Rustin GJ; Nelstrop AE; McClean P; Brady MF; McGuire WP; Hoskins WJ; Mitchell H; Lambert HE
    J Clin Oncol; 1996 May; 14(5):1545-51. PubMed ID: 8622070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of CA-125 to assess response to new agents in ovarian cancer trials.
    Rustin GJ
    J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Duska LR; Java JJ; Cohn DE; Burger RA
    Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.
    Rustin GJ; Nelstrop AE; Bentzen SM; Bond SJ; McClean P
    J Clin Oncol; 2000 Apr; 18(8):1733-9. PubMed ID: 10764434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
    Markman M; Kennedy A; Kim J
    Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
    Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
    J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
    Rustin GJ; Timmers P; Nelstrop A; Shreeves G; Bentzen SM; Baron B; Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Eisenhauer E
    J Clin Oncol; 2006 Jan; 24(1):45-51. PubMed ID: 16382112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
    Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J;
    Int J Gynecol Cancer; 2011 Feb; 21(2):419-23. PubMed ID: 21270624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
    Bridgewater JA; Nelstrop AE; Rustin GJ; Gore ME; McGuire WP; Hoskins WJ
    J Clin Oncol; 1999 Feb; 17(2):501-8. PubMed ID: 10080591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Rose PG; Fusco N; Fluellen L; Rodriguez M
    J Clin Oncol; 1998 Apr; 16(4):1494-7. PubMed ID: 9552057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy.
    Mayerhofer K; Bodner K; Bodner-Adler B; Schindl M; Kaider A; Hefler L; Zeillinger R; Leodolter S; Joura EA; Kainz C
    Cancer; 2001 Jan; 91(2):388-93. PubMed ID: 11180086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
    Rustin GJ; Nelstrop AE; Crawford M; Ledermann J; Lambert HE; Coleman R; Johnson J; Evans H; Brown S; Oster W
    J Clin Oncol; 1997 Jan; 15(1):172-6. PubMed ID: 8996139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.